Cargando…

Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy

PURPOSE: Intraoperative identification of rectal cancer (RC) can be challenging, especially because of fibrosis after treatment with preoperative chemo- and radiotherapy (CRT). Tumor-targeted fluorescence imaging can enhance the contrast between tumor and normal tissue during surgery. Promising targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Boogerd, Leonora SF, van der Valk, Maxime JM, Boonstra, Martin C, Prevoo, Hendrica AJM, Hilling, Denise E, van de Velde, Cornelis JH, Sier, Cornelis FM, Fariña Sarasqueta, Arantza, Vahrmeijer, Alexander L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870658/
https://www.ncbi.nlm.nih.gov/pubmed/29615840
http://dx.doi.org/10.2147/OTT.S145473
_version_ 1783309528137203712
author Boogerd, Leonora SF
van der Valk, Maxime JM
Boonstra, Martin C
Prevoo, Hendrica AJM
Hilling, Denise E
van de Velde, Cornelis JH
Sier, Cornelis FM
Fariña Sarasqueta, Arantza
Vahrmeijer, Alexander L
author_facet Boogerd, Leonora SF
van der Valk, Maxime JM
Boonstra, Martin C
Prevoo, Hendrica AJM
Hilling, Denise E
van de Velde, Cornelis JH
Sier, Cornelis FM
Fariña Sarasqueta, Arantza
Vahrmeijer, Alexander L
author_sort Boogerd, Leonora SF
collection PubMed
description PURPOSE: Intraoperative identification of rectal cancer (RC) can be challenging, especially because of fibrosis after treatment with preoperative chemo- and radiotherapy (CRT). Tumor-targeted fluorescence imaging can enhance the contrast between tumor and normal tissue during surgery. Promising targets for RC imaging are carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM) and the tyrosine-kinase receptor Met (c-Met). The effect of CRT on their expression determines their applicability for imaging. Therefore, we investigated whether CRT modifies expression patterns in tumors, lymph node (LN) metastases and adjacent normal rectal tissues. PATIENTS AND METHODS: Preoperative biopsies, primary tumor specimens and metastatic LNs were collected from 38 RC patients who did not receive CRT (cohort 1) and 34 patients who did (cohort 2). CEA, EpCAM and c-Met expression was determined using immunohistochemical staining and was semiquantified by a total immunostaining score (TIS), consisting of the percentage and intensity of stained tumor cells (0–12). RESULTS: In both cohorts CEA, EpCAM and c-Met were significantly highly expressed in >60% of tumor tissues compared with adjacent normal epithelium (T/N ratio, P<0.01). EpCAM showed the most homogenous expression in tumors, whereas CEA showed the highest T/N ratio. Most importantly, CEA and EpCAM expression did not significantly change in normal or neoplastic RC tissue after CRT, whereas levels of c-Met changed (P=0.02). Tissues of eight patients with a pathological complete response after CRT showed expression of all biomarkers with TIS close to normal epithelium. CONCLUSION: Histological evaluation shows that CEA, EpCAM and c-Met are suitable targets for RC imaging, because all three are significantly enhanced in cancer tissue from primary tumors or LN metastases compared with normal adjacent tissue. Furthermore, the expression of CEA and EpCAM is not significantly changed after CRT. These data underscore the applicability of c-Met and especially, CEA and EpCAM as targets for image-guided RC surgery, both before and after CRT.
format Online
Article
Text
id pubmed-5870658
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58706582018-04-03 Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy Boogerd, Leonora SF van der Valk, Maxime JM Boonstra, Martin C Prevoo, Hendrica AJM Hilling, Denise E van de Velde, Cornelis JH Sier, Cornelis FM Fariña Sarasqueta, Arantza Vahrmeijer, Alexander L Onco Targets Ther Original Research PURPOSE: Intraoperative identification of rectal cancer (RC) can be challenging, especially because of fibrosis after treatment with preoperative chemo- and radiotherapy (CRT). Tumor-targeted fluorescence imaging can enhance the contrast between tumor and normal tissue during surgery. Promising targets for RC imaging are carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM) and the tyrosine-kinase receptor Met (c-Met). The effect of CRT on their expression determines their applicability for imaging. Therefore, we investigated whether CRT modifies expression patterns in tumors, lymph node (LN) metastases and adjacent normal rectal tissues. PATIENTS AND METHODS: Preoperative biopsies, primary tumor specimens and metastatic LNs were collected from 38 RC patients who did not receive CRT (cohort 1) and 34 patients who did (cohort 2). CEA, EpCAM and c-Met expression was determined using immunohistochemical staining and was semiquantified by a total immunostaining score (TIS), consisting of the percentage and intensity of stained tumor cells (0–12). RESULTS: In both cohorts CEA, EpCAM and c-Met were significantly highly expressed in >60% of tumor tissues compared with adjacent normal epithelium (T/N ratio, P<0.01). EpCAM showed the most homogenous expression in tumors, whereas CEA showed the highest T/N ratio. Most importantly, CEA and EpCAM expression did not significantly change in normal or neoplastic RC tissue after CRT, whereas levels of c-Met changed (P=0.02). Tissues of eight patients with a pathological complete response after CRT showed expression of all biomarkers with TIS close to normal epithelium. CONCLUSION: Histological evaluation shows that CEA, EpCAM and c-Met are suitable targets for RC imaging, because all three are significantly enhanced in cancer tissue from primary tumors or LN metastases compared with normal adjacent tissue. Furthermore, the expression of CEA and EpCAM is not significantly changed after CRT. These data underscore the applicability of c-Met and especially, CEA and EpCAM as targets for image-guided RC surgery, both before and after CRT. Dove Medical Press 2018-03-23 /pmc/articles/PMC5870658/ /pubmed/29615840 http://dx.doi.org/10.2147/OTT.S145473 Text en © 2018 Boogerd et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Boogerd, Leonora SF
van der Valk, Maxime JM
Boonstra, Martin C
Prevoo, Hendrica AJM
Hilling, Denise E
van de Velde, Cornelis JH
Sier, Cornelis FM
Fariña Sarasqueta, Arantza
Vahrmeijer, Alexander L
Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
title Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
title_full Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
title_fullStr Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
title_full_unstemmed Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
title_short Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
title_sort biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870658/
https://www.ncbi.nlm.nih.gov/pubmed/29615840
http://dx.doi.org/10.2147/OTT.S145473
work_keys_str_mv AT boogerdleonorasf biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT vandervalkmaximejm biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT boonstramartinc biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT prevoohendricaajm biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT hillingdenisee biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT vandeveldecornelisjh biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT siercornelisfm biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT farinasarasquetaarantza biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy
AT vahrmeijeralexanderl biomarkerexpressioninrectalcancertissuebeforeandafterneoadjuvanttherapy